Answers are grounded in this paper and cite their sources.
The horseshoe crab, a Xiphosurid species with an ancient lineage that dates back 450 million years, has proven to be a precious asset to the pharmaceutical industry. The blood extracted from these creatures is an irreplaceable component in detecting bacterial endotoxins, crucially important in pharmaceutical and functional settings. Unfortunately, these living ancient organisms are threatened from multiple perspectives and are now considered endangered. While efforts to conserve these creatures are underway, exploring technologies for their conservation can help us understand the latest advancements in the field and shed light on areas that have not yet been targeted. This analytical report is the first of its kind in this domain and provides a comprehensive overview of the available patents associated with the conservation of horseshoe crabs. The analysis is based on an extensive dataset (413) that describes technology for conservation of these living fossils, with a focus on recombinant proteins that can be a viable alternative to the mass utilization of the horseshoe crabs for the extraction of limulus amoebocyte lysate. Other technological advances which advocate cell-free hemolymph production and the use of artificial baits to replace the traditional grassroot practices, procedures related to efficient breeding, growth, hatching and release from artificial culture systems can go a long way in the conservation of these living fossils. Transitioning to recombinant Factor C, a ban on horseshoe crab baits, diversity mapping through genetic markers and artificial breeding techniques are some of the measures that can be manifested at the policy level to enhance conservation efforts.
No takes yet. Share an insight, caveat, or question.
Mallick et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: